WHWK (Whitehawk Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $4.11
GF Value $0.27
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics FCF Margin %?

Whitehawk Therapeutics WHWK -6.16% 38 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 960 Biotechnology companies, Whitehawk Therapeutics ranks worse than 82.5% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Whitehawk Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-22.21 Mil. Whitehawk Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Whitehawk Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Whitehawk Therapeutics's current FCF Yield % is -53.03%.

The historical rank and industry rank for Whitehawk Therapeutics's FCF Margin % or its related term are showing as below:

WHWK' s FCF Margin % Range Over the Past 10 Years
Min: -2246.9   Med: -295.22   Max: -90.72
Current: -1508.44

During the past 6 years, the highest FCF Margin % of Whitehawk Therapeutics was -90.72%. The lowest was -2246.90%. And the median was -295.22%.

WHWK's FCF Margin % is ranked worse than
82.5% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs WHWK: -1508.44

Whitehawk Therapeutics FCF Margin % Related Terms

Whitehawk Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Whitehawk Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Whitehawk Therapeutics FCF Margin % Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -2,246.90 -329.15 -261.29 -235.55 -1,371.38

Whitehawk Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -173.76 0.00 0.00 0.00 0.00

WHWK vs VYGR, CRBU, OBIO: FCF Margin % Comparison

For the Biotechnology subindustry, Whitehawk Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Whitehawk Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's FCF Margin % falls into.


WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Whitehawk Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Whitehawk Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-97.985/7.145
=-1,371.38 %

Whitehawk Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-22.208/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Whitehawk Therapeutics (WHWK) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Whitehawk Therapeutics and its competitors. According to the industry distribution chart, Whitehawk Therapeutics ranks #792 out of 960 companies in the Biotechnology industry, placing it in the top 82.5%.
Is Whitehawk Therapeutics' FCF Margin % too high?
Whitehawk Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Whitehawk Therapeutics ranks #792 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' FCF Margin % compare to VYGR and CRBU?
According to the Biotechnology industry distribution chart, Whitehawk Therapeutics ranks #792 out of 960 companies for FCF Margin %. This places Whitehawk Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.11 — trading 1422.2% above its estimated fair value. The current FCF Margin % is 0.00%. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $4.11 is trading 1422.2% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • FCF Margin %: 0.00%
  • GF Value™: $0.27 vs. price of $4.11 (1422.2% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$0.27
GF Value